Sofosbuvir 400mg + Ledipasvir 90 mg

$12.00

Product Name        : Soforel-LP

Generic Name        : Sofosbuvir+ Ledipasvir
Formulation         : Tablet

Available Pack size : 6

Strengths           : 400 mg+ 90mg

Manufacturer: Beacon Pharmaceuticals Ltd.

Indications

Ledipasvir and Sofosbuvir combination is indicated for the treatment of chronic hepatitis C (CHC) genotype 1, 4 & 6 infection in adults.

Pharmacology

It is a fixed-dose combination tablet containing Ledipasvir and Sofosbuvir for oral administration. Ledipasvir is an HCV NS5A inhibitor and Sofosbuvir is a nucleotide analog inhibitor of HCV NS5B polymerase.

Dosage & Administration

Recommended dosage: One tablet (90 mg of Ledipasvir and 400 mg of Sofosbuvir) taken orally once daily with or without food

Recommended treatment duration:

  • Treatment-naive with or without cirrhosis: 12 weeks
  • Treatment-experienced without cirrhosis: 12 weeks
  • Treatment-experienced with cirrhosis: 24 weeks

A dose recommendation cannot be made for patients with severe renal impairment or end stage renal disease.

Interaction

  • Coadministration with amiodarone may result in serious symptomatic bradycardia. Use of Soforel-LP combination with Amiodarone is not recommended
  • P-gp inducers (e.g., Rifampin, St. John’s wort): May alter concentrations of Ledipasvir and Sofosbuvir. Use of Ledipasvir and Sofosbuvir combination with P-gp inducers is not recommended

Contraindications

This combination is contraindicated in patients with Known hypersensitivity to Ledipasvir, Sofosbuvir or any other ingredient in the product.

Side Effects

The most common adverse reactions with treatment with Ledipasvir and Sofosbuvir combination for 8, 12, or 24 weeks are fatigue and headache.

Pregnancy & Lactation

Pregnancy Category B. There are no adequate and well-controlled studies with Ledipasvir and Sofosbuvir in pregnant women. Because animal reproduction studies are not always predictive of human response, this should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation: It is not known whether Ledipasvir and Sofosbuvir and its metabolites are present in human breast milk.

Precautions & Warnings

Bradycardia with Amiodarone coadministration: Serious symptomatic bradycardia may occur in patients taking Amiodarone, particularly in patients also receiving beta blockers, or those with underlying cardiac comorbidities and/or advanced liver disease. Coadministration of Amiodarone with Ledipasvir and Sofosbuvir combination is not recommended. In patients without viable treatment options, cardiac monitoring is recommended.

Use with other drugs containing sofosbuvir, is not recommended

Use in Special Populations

Pediatric Use: Safety and effectiveness of Soforel-LP have not been established in pediatric patients.

Geriatric Use: No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients. No dosage adjustment of Soforel-LP is warranted in geriatric patients.

Overdose Effects

No specific antidote is available for overdose

Therapeutic Class

Hepatic viral infections (Hepatitis C)

Storage Conditions

Keep out of the reach of children. Keep in a cool & dry place. Protect from light.

Product Name        : Soforel-LP

Generic Name        : Sofosbuvir+ Ledipasvir
Formulation         : Tablet

Available Pack size : 6

Strengths           : 400 mg+ 90mg

Manufacturer: Beacon Pharmaceuticals Ltd.

See Our More Products CLICK HERE

Reviews

There are no reviews yet.

Be the first to review “Sofosbuvir 400mg + Ledipasvir 90 mg”

Your email address will not be published. Required fields are marked *

Shopping Cart